Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Drug Safety Website Under Development As One Response To Concerns

Executive Summary

FDA is understood to be developing a drug safety website as part of an initiative to address concerns about post-marketing surveillance

You may also be interested in...



FDA Unveils Rx Safety Board, Website; Postmarket Surveillance Overhaul Next

HHS is planning a major overhaul of FDA's postmarketing surveillance system as the centerpiece of its next announcement about upgrades to the drug safety regulatory system

FDA Unveils Rx Safety Board, Website; Postmarket Surveillance Overhaul Next

HHS is planning a major overhaul of FDA's postmarketing surveillance system as the centerpiece of its next announcement about upgrades to the drug safety regulatory system

Drug Safety Concerns Will Increase FDA-Industry Interactions, Schering Says

Schering-Plough predicts that increased attention on drug safety issues will drive greater interactions with FDA

Related Content

Topics

UsernamePublicRestriction

Register

LL038093

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel